

## SAFETY DATA SHEET



### 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND OF THE COMPANY/UNDERTAKING

<b>Material</b>	<b>TELZIR ORAL SUSPENSION</b>
<b>Synonym(s)</b>	TELZIR ORAL SUSPENSION 50 MG/ML * LEXIVA ORAL SUSPENSION 50 MG/ML * GW433908G ORAL SUSPENSION * NDC NO: 0173-0727-00 * FOSAMPRENAVIR CALCIUM, FORMULATED PRODUCT
<b>Company Name</b>	<p>GlaxoSmithKline, Corporate Environment, Health &amp; Safety 980 Great West Road Brentford, Middlesex TW8 9GS UK</p> <p>UK General Information: +44-20-8047-5000 Transport Emergency (EU) +44-1865-407333 Medical Emergency +1-612-221-3999, Ext 221 Information and Advice: US number, available 24 hours Multi-language response</p> <p>GlaxoSmithKline, Corporate Environment, Health &amp; Safety One Franklin Plaza, 200 N 16th Street Philadelphia, PA 19102-1225 US</p> <p>US General Information: +1-888-825-5249 Transport Emergency (non EU) +1-703-527-3887 US number, available 24 hours Multi-language response</p>

### \* 2. COMPOSITION / INFORMATION ON INGREDIENTS

Ingredients	CAS #	Percent	EC-No.
FOSAMPRENAVIR CALCIUM	226700-81-8	6.1	
NON-HAZARDOUS INGREDIENTS	Unassigned	93.9	

### 3. HAZARDS IDENTIFICATION

<b>Fire and Explosion</b>	Expected to be non-combustible.
<b>Health</b>	Caution - Pharmaceutical agent. Exposure might occur via skin; eyes. Health effects information is based on hazards of components.
<b>Environment</b>	No information is available about the potential of this product to produce adverse environmental effects.

### 4. FIRST-AID MEASURES

<b>Ingestion</b>	Never attempt to induce vomiting. Do not attempt to give any solid or liquid by mouth if the exposed subject is unconscious or semi-conscious. Wash out the mouth with water. If the exposed subject is fully conscious, give plenty of water to drink. Obtain medical attention.
<b>Inhalation</b>	Physical form suggests that risk of inhalation exposure is negligible.
<b>Skin Contact</b>	Using appropriate personal protective equipment, remove contaminated clothing and flush exposed area with large amounts of water. Obtain medical attention if skin reaction occurs, which may be immediate or delayed.

Material TELZIR ORAL SUSPENSION

**Eye Contact** Wash immediately with clean and gently flowing water. Continue for at least 15 minutes. Obtain medical attention.

**NOTES TO HEALTH PROFESSIONALS**

**Medical Treatment** Medical treatment in cases of overexposure should be treated as an overdose of an anti-viral agent. Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information centre.

**Medical Conditions Caused or Aggravated by Exposure** None for occupational exposure.

**Health Surveillance Procedures** Pre-placement and periodic health surveillance is not usually indicated. The final determination of the need for health surveillance should be determined by local risk assessment.

**Antidotes** No specific antidotes are recommended.

## 5. FIRE-FIGHTING MEASURES

**Fire and Explosion Hazards** Not expected for the product, although the packaging is combustible.

**Extinguishing Media** Water or foam extinguishers are recommended. Carbon dioxide or dry powder extinguishers may be ineffective.

**Special Firefighting Procedures** For single units (packages): No special requirements needed. For larger amounts (multiple packages/pallets) of product: Since toxic, corrosive or flammable vapours might be evolved from fires involving this product and associated packaging, self contained breathing apparatus and full protective equipment are recommended for firefighters. If possible, contain and collect firefighting water for later disposal.

**Hazardous Combustion Products** Toxic, corrosive or flammable thermal decomposition products are expected when the product is exposed to fire.

## 6. ACCIDENTAL RELEASE MEASURES

**Personal Precautions** Wear protective clothing and equipment consistent with the degree of hazard.

**Environmental Precautions** For large spills, take precautions to prevent entry into waterways, sewers, or surface drainage systems.

**Clean-up Methods** Collect and place it in a suitable, properly labelled container for recovery or disposal.

**Decontamination Procedures** No specific decontamination or detoxification procedures have been identified for this product.

## 7. HANDLING AND STORAGE

**HANDLING**

**General Requirements** No special control measures required for the normal handling of this product.

**STORAGE**

No storage requirements necessary for occupational hazards. Follow product information storage instructions to maintain efficacy.

## 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

**INGREDIENT** FOSAMPRENAVIR CALCIUM

**GSK Occupational Hazard Category** 1

**GSK Occupational Exposure Limit** 1750 mcg/m<sup>3</sup> (8 HR TWA)

**Other Equipment or Procedures** None required for normal handling. Wash hands and arms thoroughly after handling.

Material TELZIR ORAL SUSPENSION

## 9. PHYSICAL AND CHEMICAL PROPERTIES

**Appearance**

**Physical Form** Suspension.

## 10. STABILITY AND REACTIVITY

**Stability** This product is expected to be stable.

**Conditions to Avoid** None for normal handling of this product.

## 11. TOXICOLOGY INFORMATION

**Pharmacological Effects** This preparation contains ingredient(s) with the following activity: a protease inhibitor.

**Routes of Exposure**

**Oral Toxicity** Not expected to be toxic following ingestion.

**Inhalation Toxicity** No studies have been conducted.

**Skin Effects** Irritation is not expected following direct contact.

**Eye Effects** Minor irritation might occur following direct contact with eyes.

**Sensitisation** Sensitisation (allergic skin reaction) is not expected.

**Genetic Toxicity** Not expected to be genotoxic under occupational exposure conditions.

**Carcinogenicity** Not expected to produce cancer in humans under occupational exposure conditions.

**Reproductive Effects** Not expected to produce adverse effects on fertility or development under occupational exposure conditions.

**Other Adverse Effects** Overexposure in the workplace might have the following effects: toxicity to the liver resulting in abnormal blood chemistry.

## 12. ECOLOGICAL INFORMATION

**Summary** No information is available about the potential of this product to produce adverse environmental effects. This material contains an active pharmaceutical ingredient that has been tested, and no environmental effects have been identified. Local regulations and procedures should be consulted prior to environmental release.

Specific information on the active pharmaceutical ingredient is provided below.

**ECOTOXICITY****Aquatic**

**Activated Sludge Respiration** This material contains an active pharmaceutical ingredient that is not toxic to activated sludge microorganisms.

IC50: > 1451 mg/l, 3 Hours, Activated sludge

**Algal** This material contains an active pharmaceutical ingredient that is not toxic to algae.

IC50: > 100 mg/l, 72 Hours, Scenedesmus subspicatus, green algae, Static test

NOEC: 100 mg/l, 72 Hours, Scenedesmus subspicatus, green algae, Static test

**Daphnid** This material contains an active pharmaceutical ingredient that is not toxic to daphnids. This material contains an active pharmaceutical ingredient that is not harmful to daphnids in chronic toxicity studies.

EC50: > 109 mg/l, 48 Hours, Daphnia magna

NOEC: > 109 mg/l, 48 Hours, Daphnia magna

Chronic LOEC: > 100 mg/l, 8 Days, Ceriodaphnia dubia, Static renewal test

Chronic NOEC: 100 mg/l, 8 Days

**Fish** This material contains an active pharmaceutical ingredient that is not toxic to fish.

Material TELZIR ORAL SUSPENSION

Juvenile Oncorhyncus mykiss, rainbow trout  
 EC50: > 100 mg/l, 96 Hours, Static renewal test  
 Juvenile Oncorhyncus mykiss, rainbow trout  
 NOEC: 100 mg/l, 96 Hours, Static renewal test

**MOBILITY****Solubility**

This material contains an active pharmaceutical ingredient that for environmental fate predictions has limited solubility in water.

**Volatility**

This material contains an active pharmaceutical ingredient that will not readily enter into the air from hard surfaces or from a container of the pure substance.

**Partitioning**

This material contains an active pharmaceutical ingredient with octanol/water partition coefficient data that suggests that for environmental fate predictions the active pharmaceutical ingredient will not have the tendency to distribute into fats.

**PERSISTENCE/DEGRADATION****Hydrolysis**

This material contains an active pharmaceutical ingredient that has been shown to be chemically stable in water. Hydrolysis is unlikely to be a significant depletion mechanism.

Half-Life, Neutral: > 1 Years, Measured

**Biodegradation**

This material contains an active pharmaceutical ingredient that is not readily biodegradable but is inherently biodegradable (as defined by 1993 OECD Testing Guidelines) and is not expected to persist in the environment.

Aerobic - Ready

Percent Degradation: 1 %, 28 days

Aerobic - Inherent

Percent Degradation: 17 %, 28 days, Modified Zahn-Wellens, DOC removal., Activated sludge

Aerobic - Inherent

Percent Degradation: 100 %, 28 days, Modified Zahn-Wellens, primary biodegradation, loss of parent., Activated sludge

## 13. DISPOSAL CONSIDERATIONS

**Disposal Recommendations**

Collect for recycling or recovery if possible. The disposal method for rejected products/returned goods must ensure that they cannot be re-sold or re-used.

**Regulatory Requirements**

Observe all local and national regulations when disposing of this product.

## 14. TRANSPORT INFORMATION

The SDS should accompany all shipments for reference in the event of spillage or accidental release. Only authorised persons trained and competent in accordance with appropriate national and international regulatory requirements may prepare dangerous goods for transport.

**UN Classification and Labelling****Transport Information**

Transportation and shipping of this product is not restricted. It has no known, significant hazards requiring special packaging or labelling for air, maritime, US or European ground transport purposes.

## 15. REGULATORY INFORMATION

The information included below is an overview of the major regulatory requirements. It should not be considered to be an exhaustive summary. Local regulations should be consulted for additional requirements.

**EU Classification and Labelling**

Exempt from requirements of EU Dangerous Preparations directive - product regulated as a medicinal product, cosmetic product or medical device.

**US OSHA Standard (29 CFR Part 1910.1200)****Classification**

This product is classified as hazardous according to the OSHA Hazard Communication Standard.

Material TELZIR ORAL SUSPENSION

---

**Other US Regulations****TSCA Status**

Exempt

**Australian Classification**

This product is not classified as hazardous according to the NOHSC Approved Criteria for Classifying Hazardous Substances.

**according to Hazardous****Substance and Dangerous****Goods Regulatory Framework**

<b>16. OTHER INFORMATION</b>
------------------------------

**References**

GSK Hazard Determination

**SDS Version Number**

3

**SDS Sections Updated****Sections****Subsections**

COMPOSITION / INFORMATION ON INGREDIENTS

The information and recommendations in this safety data sheet are, to the best of our knowledge, accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.